Peter Zerhouni new CEO of InDex
This article was originally published in Scrip
InDex Pharmaceuticals has named Peter Zerhouni its new CEO. Mr Zerhouni joins the company, which is developing lead product Kappaproct as a treatment of severe ulcerative colitis, from Diamyd Medical where he was also CEO. He succeeds Jesper Wiklund, who led the company since 2011.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.